RETISERT ® (fluocinolone acetonide intravitreal implant) 0.59 mg is a corticosteroid indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye.

RETISERT ® (fluocinolone acetonide intravitreal implant) 0.59 mg is a corticosteroid indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye.

RETISERT™ (fluocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye at a nominal initial...

2024年1月18日 · RETISERT is a corticosteroid indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. (1) RETISERT is designed to …

2023年7月12日 · Retisert is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. It is a corticosteroid used to treat inflammation within the eye …

Retisert ophthalmic implant is used to treat non-infectious posterior uveitis, inflammation that affects the back of the eye. Retisert slowly releases fluocinolone into the eye over a period of …

2024年1月23日 · RETISERT ® (fluocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye …

2023年3月13日 · Retisert (fluocinolone acetonide intravitreal implant) is a corticosteroid used to treat inflammation within the eye that may be caused by a variety of diseases or infections. …

2006年4月1日 · The fluocinolone implant, Retisert, is the first U.S. Food and Drug Administration (FDA) approved treatment for non-infectious intermediate, posterior, or panuveitis. The …

RETISERT (fluocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye at a nominal initial …